AID TB resistance line probe assay for rapid detection of resistant Mycobacterium tuberculosis in clinical samples

Molina-Moya, Bárbara; Lacoma, Alícia; Prat, Cristina; Díaz, J.F.; Dudnyk, Andrii; Haba, L.; Maldonado, José; Samper, Sofía; Ruiz-Manzano, Juan; Ausina, Vicente; Domínguez, José

doi:10.1016/j.jinf.2014.09.010

Cited by 27 publications

(20 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 The clinical significance of strains with a mutation in the presence of a susceptible phenotypic result is as yet unclear. 98,99 A second generation GenoType MTBDRsl is currently under evaluation: the main differences consist in the addition of the mutation in the eis gene associated with resistance to KM and in the absence of codon 306 of embB.…”

Section: Principle Of Genotypic Drug Susceptibility Testingmentioning

confidence: 99%

“…The assay flags the presence of resistance in the absence of binding of wt probes to the target sequence. The pooled sensitivity and specificity of Xpert for RMP detection are respectively 95% (95% confidence interval [CI] 90-97) and 98% (95%CI [97][98][99]. The test is recommended by the WHO as the initial diagnostic test for adults and children presumed to have MDR-TB or human immunodeficiency virus (HIV) associated TB.…”

Section: Xpert Mtb/rifmentioning

confidence: 99%

See 1 more Smart Citation

Clinical implications of molecular drug resistance testing for <I>Mycobacterium tuberculosis</I>: a TBNET/RESIST-TB consensus statement

Domínguez

Boettger

Cirillo

et al. 2016

int j tuberc lung dis

Self Cite

122

105

View full text Add to dashboard Cite

Section: Principle Of Genotypic Drug Susceptibility Testingmentioning

confidence: 99%

Section: Xpert Mtb/rifmentioning

confidence: 99%

Clinical implications of molecular drug resistance testing for <I>Mycobacterium tuberculosis</I>: a TBNET/RESIST-TB consensus statement

Domínguez

Boettger

Cirillo

et al. 2016

int j tuberc lung dis

Self Cite

122

105

View full text Add to dashboard Cite

“… Mindru 2013 Data insufficient for 2 x 2 tables. Molina‐Moya 2015 Test other than MTBDR sl . Niehaus 2015 Not a diagnostic accuracy study.…”

Section: Characteristics Of Excluded Studies [Ordered By Study Id]mentioning

confidence: 99%

GenoType^® MTBDRsl assay for resistance to second-line anti-tuberculosis drugs

Theron

Peter

Richardson

et al. 2016

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Genotype® MTBDR sl (MTBDR sl ) is a rapid DNA‐based test for detecting specific mutations associated with resistance to fluoroquinolones and second‐line injectable drugs (SLIDs) in Mycobacterium tuberculosis complex. MTBDR sl version 2.0 (released in 2015) identifies the mutations detected by version 1.0, as well as additional mutations. The test may be performed on a culture isolate or a patient specimen, which eliminates delays associated with culture. Version 1.0 requires a smear‐positive specimen, while version 2.0 may use a smear‐positive or ‐negative specimen. We performed this updated review as part of a World Health Organization process to develop updated guidelines for using MTBDR sl . Objectives To assess and compare the diagnostic accuracy of MTBDR sl for: 1. fluoroquinolone resistance, 2. SLID resistance, and 3. extensively drug‐resistant tuberculosis, indirectly on a M. tuberculosis isolate grown from culture or directly on a patient specimen. Participants were people with rifampicin‐resistant or multidrug‐resistant tuberculosis. The role of MTBDR sl would be as the initial test, replacing culture‐based drug susceptibility testing (DST), for detecting second‐line drug resistance. Search methods We searched the following databases without language restrictions up to 21 September 2015: the Cochrane Infectious Diseases Group Specialized Register; MEDLINE; Embase OVID; Science Citation Index Expanded, Conference Proceedings Citation Index‐Science, and BIOSIS Previews (all three from Web of Science); LILACS; and SCOPUS; registers for ongoing trials; and ProQuest Dissertations & Theses A&I. We reviewed references from included studies and contacted specialists in the field. Selection criteria We included cross‐sectional and case‐control studies that determined MTBDR sl accuracy against a defined reference standard (culture‐based DST, genetic sequencing, or both). Data collection and analysis Two review authors independently extracted data and assessed quality using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS‐2) tool. We synthesized data for versions 1.0 and 2.0 separately. We estimated MTBDR sl sensitivity and specificity for fluoroquinolone resistance, SLID resistance, and extensively drug‐resistant tuberculosis when the test was performed indirectly or directly (smear‐positive specimen for version 1.0, smear‐positive or ‐negative specimen for version 2.0). We explored the influence on accuracy estimates of individual drugs within a drug class and of different reference standards. We performed most analyses using a bivariate random‐effects model with culture‐based DST as reference ...

show abstract

“…Resistance to FLQ is associated with mutations in the quinolone resistance determining region (QRDR) in gyrA, and to a lesser extent in gyrB. The reference molecular method to detect these mutations is sequencing, but different methods based on reverse hybridization [12][13][14], real-time PCR or pyrosequencing [15] have also been developed [16][17][18][19][20]. In a previous work, we In Table 3 are presented the mutations detected in the different loci analyzed.…”

Section: Introductionmentioning

confidence: 99%

Pyrosequencing for rapid detection of Mycobacterium tuberculosis second-line drugs and ethambutol resistance

Lacoma

Molina-Moya

Prat

et al. 2015

Diagnostic Microbiology and Infectious Disease

View full text Add to dashboard Cite

AID TB resistance line probe assay for rapid detection of resistant Mycobacterium tuberculosis in clinical samples

Cited by 27 publications

References 44 publications

Clinical implications of molecular drug resistance testing for <I>Mycobacterium tuberculosis</I>: a TBNET/RESIST-TB consensus statement

Clinical implications of molecular drug resistance testing for <I>Mycobacterium tuberculosis</I>: a TBNET/RESIST-TB consensus statement

GenoType^® MTBDRsl assay for resistance to second-line anti-tuberculosis drugs

Pyrosequencing for rapid detection of Mycobacterium tuberculosis second-line drugs and ethambutol resistance

Contact Info

Product

Resources

About

AID TB resistance line probe assay for rapid detection of resistant Mycobacterium tuberculosis in clinical samples

Cited by 27 publications

References 44 publications

Clinical implications of molecular drug resistance testing for <I>Mycobacterium tuberculosis</I>: a TBNET/RESIST-TB consensus statement

Clinical implications of molecular drug resistance testing for <I>Mycobacterium tuberculosis</I>: a TBNET/RESIST-TB consensus statement

GenoType® MTBDRsl assay for resistance to second-line anti-tuberculosis drugs

Pyrosequencing for rapid detection of Mycobacterium tuberculosis second-line drugs and ethambutol resistance

Contact Info

Product

Resources

About

GenoType^® MTBDRsl assay for resistance to second-line anti-tuberculosis drugs